Evidence map›Paper›PMID 35882950›Full record

ArticleProstate cancer and prostatic diseases2023

Intensity of observation with active surveillance or watchful waiting in men with prostate cancer in the United States.

Bashir Al Hussein Al Awamlh, Xian Wu, Daniel A Barocas, Kelvin A Moses, Richard M Hoffman, Spyridon P Basourakos, Patrick Lewicki, Woodson W Smelser, Camilo Arenas-Gallo, Jonathan E Shoag

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bashir Al Hussein Al AwamlhDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. Bashir.alhussein@vumc.org.
Xian WuDivision of Biostatistics and Epidemiology, Department of Healthcare Policy & Research, Weill Cornell Medicine, New York, NY, USA.
Daniel A BarocasDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Kelvin A MosesDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Richard M HoffmanDepartment of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.ORCID 0000-0002-4714-7726
Spyridon P BasourakosDepartment of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-7458-4593
Patrick LewickiDepartment of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.
Woodson W SmelserDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA.
Camilo Arenas-GalloUniversity Hospitals Cleveland Medical Center, Urology Institute, Cleveland, OH, USA.ORCID 0000-0003-1549-9556
Jonathan E ShoagDepartment of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPopulation-based studies assessing various active surveillance (AS) protocols for prostate cancer, to date, have inferred AS participation by the lack of definitive treatment and use of post-diagnostic testing. This is problematic as evidence suggests that most men do not adhere to AS protocols. We sought to develop a novel method of identifying men on AS or watchful waiting (WW) independent of post-diagnostic testing and aimed to identify possible predictors of follow-up intensity in men on AS/WW.

methodsA predictive model was developed using SEER watchful waiting data to identify men ≥66 years on AS between 2010-2015, irrespective of post-diagnostic testing, and applied to SEER-Medicare database. AS intensity among different variables including age, prostate-specific antigen (PSA) level, number of total and positive biopsy cores, Charlson comorbidity index, race (Black vs. non-Black), US census region, and county poverty, income, and education levels were compared using multivariable regression analyses for PSA testing, surveillance biopsy, and magnetic resonance imaging (MRI).

resultsA total of 2238 men were identified as being on AS. Of which, 81%, 33%, and 10% had a PSA test, surveillance biopsy, and MRI scan within 1-2 years, respectively. On multivariable analyses, Black men were less likely to have a PSA test (adjusted rate ratio [ARR] 0.60, 95% CI: 0.53-0.69), MRI scan (ARR 0.40, 95% CI: 0.24-0.68), and surveillance biopsy (ARR 0.71, 95% CI: 0.55-0.92) than non-Black men. Men within the highest income quintile were more likely to undergo PSA test (ARR 1.16, 95% CI: 1.05-1.27) and MRI scan (ARR 1.60, 95% CI 1.15-2.27) compared to men with the lowest income.

conclusionsBlack men and men with lower incomes on AS underwent less rigorous monitoring. Further study is needed to understand and ameliorate differences in AS rigor stemming from sociodemographic differences.

Indexed as

Prostatic NeoplasmsAgedBiopsyHumansMaleMedicareProstate-Specific AntigenUnited StatesWatchful WaitingProstate-Specific Antigen

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.